Endothelial Progenitor Cells in Umbilical Cord Blood in Preeclampsia and IUGR
NCT ID: NCT00634855
Last Updated: 2018-06-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
11 participants
OBSERVATIONAL
2008-03-31
2012-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Consequences of Antiangiogenic Factors Involved in Preeclampsia on Intra-uterine Growth Restricted Preterm Newborn
NCT01648855
Placental Growth and Adverse Pregnancy Outcomes
NCT01669525
Low-molecular-weight Heparin in Constituted Vascular Intrauterine Growth Restriction
NCT02672566
Interest of Circulating Endothelial Biomarkers in Vascular Pregnancy Complications
NCT00485784
Maternal Left Lateral Position in Fetal Growth Restriction
NCT06919692
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
To date, the cause of preeclampsia is not known although many agree that preeclampsia is a two-stage disease as described by Roberts et al. with the placenta of central importance. The first stage involves poor placental perfusion usually a result of impaired vascular remodeling in early pregnancy or from maternal disease. This leads to the second stage, which is the maternal syndrome of preeclampsia and involves both endothelial and leukocyte activation.
Preeclampsia is associated with an increased maternal cardiovascular risk later in life. Women with a history of preeclampsia demonstrate altered expression of angiogenesis-related proteins and increased insulin resistance as measured by the homeostasis model of insulin resistance. Additionally, preeclampsia is associated with an increase in future cardiovascular risk in the fetus.
Endothelial dysfunction and abnormal regulation of vascular tone that is present in preeclampsia suggests abnormal development of vascular cells such as endothelial progenitor cells. The increased cardiovascular risk of neonates born in the setting of IUGR and preeclampsia also suggests the possibility of abnormal development of endothelial progenitor cells in the fetal compartment in these disease states. The purpose of this pilot project is to determine the effects of preeclampsia/IUGR on endothelial progenitor cells derived from fresh umbilical cord blood.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Complicated
Women with pregnancies complicated by intrauterine growth restriction or preeclampsia
No interventions assigned to this group
Normal
Women with normal pregnancies
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Gestational age between 30-40 weeks plus:
* Uncomplicated pregnancy or
* Fetal estimated weight \<10% for gestational age or abdominal circumference \<5% or
* Preeclampsia by ACOG criteria:
1. HTN \> 140/90 on two occasions
2. Proteinuria \> 300mg on 24 hour urine specimen or 1+ on urine dip
Exclusion Criteria
* Congenital abnormalities
* Multiple gestations
* Clinical Chorioamnionitis
* Recent infectious disease (within 2 weeks)
18 Years
45 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of South Carolina
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Medical University of South Carolina
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ashley Ryan, MD
Role: PRINCIPAL_INVESTIGATOR
Medical University of South Carolina
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical University of South Carolina
Charleston, South Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HR # 17821
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.